Max BioPharma

Our vision is to bring this to the world, all while making therapies much more affordable for patients. Maxwell was founded using artificial intelligence to analyze the proteomics of how the body heals itself, and what peptides in the body decline with age leading to the hallmarks of biological aging. Our civilization has become fragile due to the last pandemic. Founded in 2016, Maxwell is a preclinical stage biotechnology company targeting viruses, bacteria, fungi, and biofilm formations, including those that cause many currently untreatable infectious diseases.

Biopharmax is a global design and construction provider of manufacturing facilities and systems for Biotechnology, Pharmaceutical and synthesis API manufacturers. For over 40 years Biopharmax has catered to industry leaders around the world and has gained unique capabilities in process engineering and technology transfer related projects. Biopharmax provides Turnkey based solutions, having all end-to-end disciplines under one roof. Changes company name to biopharmax Group Keeping the focus on Pharmaceutical Industry, Changed Mission and Build (Turnkey approach), identified and defined WFI as a key core strength in strategy. Biopharmax undertakes projects from the URS/pre-concept stage through the implementation stage all the way to successful validation. Biopharmax process design expertise combined with Turnkey execution assures our clients a cutting edge production facility completed on time, within budget and with full compliance to the required regulatory standards. Biopharmax is involved in many parts of project aspects, as well as a variety of industries. Sarel Chen-Tov, Biopharmax CEO, a special interview at Kikar Shabbat news channel.

Our mission is to help people with endocrine disorders live fuller and healthier lives. By combining deep expertise in peptide discovery and development, MBX Biosciences is pioneering a new era of peptide therapeutics that confront the challenges of managing endocrine diseases. As both individuals and an organization, we are driven to make a positive impact in the world; that’s why we do what we do. Spanning hiring to company culture to product development, we are guided by our core values to help us reach our goals swiftly, responsibly, and efficiently. Translating leading-edge science into transformative medicines accessible to people in need of them. MBX was founded by pioneers in the endocrine drug development field and is led by a team of seasoned industry veterans with a common goal to transform the treatment of endocrine disorders and improve people’s lives. Hawryluk co-founded Marcadia Biotech and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia, a pioneer in peptide multi-agonists of incretin receptors, was acquired by Roche in December 2010.

Our mission is to create diagnostic products that are affordable, accessible, and enable actionable testing to improve patient outcomes. We are a dynamic and fast-growing business with a team of talented, dedicated, and ambitious people. Join us on our mission to deliver more effective and accessible healthcare. MaximBio, a leading Maryland-based manufacturer specializing in lateral flow and diagnostic devices, is announcing the receipt of a $49.5 million award from the U.S. MaximBio is proud to announce it has signed a new agreement with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADx® ) initiative. Founded in 2005, Maxim Biomedical (MaximBio) is a leading diagnostic healthcare company enhancing global health through the development and manufacture of trusted diagnostic solutions. Our technologies enable many of today’s leading diagnostic tests and we are proud to be at the frontline of diagnostic innovation to help advance the quality of healthcare. We offer decades of experience in the development and manufacturing of IVD medical device systems and in vitro diagnostic devices.

We are leveraging this technology to deliver safe, efficacious and long-acting drugs against previously undruggable targets. Using our revolutionary KnotBody® technology, we are creating first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases. Cardiovascular disease is the leading cause of death globally. Cardiovascular disease is the leading cause of death globally. Prior to joining Maxion, Arndt has served as the Chief Scientific Officer of Affimed and held executive leadership roles as Executive Vice President of R&D at Kymab (acquired by Sanofi) and Chief Development Officer at MorphoSys as well as senior leadership roles at Genentech. Aneesh is the co-inventor of KnotBody® technology and co-founder of Maxion Therapeutics and IONTAS. Aneesh has over 10 years of experience in antibody and protein drug discovery against challenging targets at AstraZeneca, University of Cambridge and IONTAS. Lucy is an investor in BGF’s early-stage team, with a focus on life sciences.

MAXONA was founded with the goal of addressing the needs of those searching for safe and efficacious remedies as alternatives to NSAIDs and opioid analgesics for the treatment of pain. We have adopted a comprehensive patent strategy and built a suite of applied and issued patents covering multiple Compositions of Matter and Methods of Use for MAX-001 targeted at a variety of disorders of pain. MAX-001 aims to deliver opioid level efficacy without the associated clinical and societal side effects. The pain market is the single largest therapeutic category with over 100 million Americans affected. MAXONA Pharmaceuticals is a clinical-stage company committed to leveraging an ex-U.S. Hence, there is a significant need for safe and efficacious alternative analgesics. This application is part of MAXONA’s patent strategy for MAX-001 and once issued should provide patent protection until September 2037. April 2019 – “FDA pre-IND feedback provides clarity on MAX-001 development plans and a roadmap to NDA filing” ​ November 2017 – The U.S.